Clinical Trial Update: MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describing a Phase 1/2 study of MEK162 in combination with imatinib mesylate for untreated advanced gastrointestinal stromal tumor, spon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)
• MEK162 (binimetinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Gastrointestinal Stromal Tumor (GIST) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING